Literature DB >> 8184108

Planned and unplanned gaps in radiotherapy: the importance of gap position and gap duration.

K Skladowski1, M G Law, B Maciejewski, G G Steel.   

Abstract

Local tumour control in 971 patients with squamous carcinoma of the supraglottic larynx has been examined in relation to the occurrence of gaps in radiation therapy. The minimum follow-up time was 3 years. The reasons for a gap in radiotherapy fell into four categories: independent of the patient (national holidays, machine break-down, etc.), planned gaps (split-course therapy), severe normal-tissue reactions, and intercurrent disease. Only 11.7% of patients had no gap at all, 75.5% a single gap, and 2.1% had more than four gaps. The probability of tumour control increased with dose in all patient sub-groups; the average percentage increase for a 1% increase in dose was 4.3. The data were subjected to multivariate analysis, leading to the following conclusions. Patients in whom there was a single gap showed a remarkable trend of local control: if the gap began before day 19 after the start of therapy, the local tumour control was considerably below that in patients who did not suffer a gap in treatment. The local tumour control in patients whose gap began at day 20-29 was indistinguishable from that in patients who had no gap in treatment. A gap further towards the end of treatment was again associated with a severe drop in local control. This trend was independent of the recorded cause of the gap. The mechanism of this phenomenon is not clear. The effect of the timing of a treatment gap appears in this data set to have had a considerable impact on outcome and our observations should stimulate further study of this phenomenon in other clinical settings.

Entities:  

Mesh:

Year:  1994        PMID: 8184108     DOI: 10.1016/0167-8140(94)90039-6

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  23 in total

1.  Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays.

Authors:  M Maciá I Garau; J Solé Monné; M J Cambra Serés; C Monfà Binefa; M Peraire Llopis
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

2.  [Reasons for the terms "radiosurgery" and "Gamma Knife"].

Authors:  K Hamm; G Surber
Journal:  HNO       Date:  2017-09       Impact factor: 1.284

Review 3.  Management of interruptions in radiotherapy treatments: Adaptive implementation in high workload sites.

Authors:  Gustavo Pozo; Maria Angeles Pérez-Escutia; Ana Ruíz; Alejandro Ferrando; Ana Milanés; Eduardo Cabello; Raul Díaz; Alejandro Prado; Jose Fermin Pérez-Regadera
Journal:  Rep Pract Oncol Radiother       Date:  2019-02-26

4.  High-dose rate intracavitary irradiation for carcinoma of the uterine cervix. The adverse effect of treatment prolongation.

Authors:  M Chatani; Y Matayoshi; N Masaki; T Inoue
Journal:  Strahlenther Onkol       Date:  1997-07       Impact factor: 3.621

5.  High-dose radiotherapy alone for patients with T4-stage laryngeal cancer.

Authors:  A Mucha-Małecka; K Składowski
Journal:  Strahlenther Onkol       Date:  2013-07-05       Impact factor: 3.621

6.  Radiation therapy for early glottic carcinoma (T1N0M0). The adverse effect of treatment interruption.

Authors:  M Chatani; Y Matayoshi; N Masaki; T Teshima; T Inoue
Journal:  Strahlenther Onkol       Date:  1997-10       Impact factor: 3.621

7.  Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy.

Authors:  Audrey Rambeau; Radj Gervais; Dominique De Raucourt; Emmanuel Babin; Audrey Emmanuelle Dugué; Carmen Florescu; David Blanchard; Bernard Gery
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-04-05       Impact factor: 2.503

8.  Inhibition of the Continuum of Radiation-Induced Normal Tissue Injury by a Redox-Active Mn Porphyrin.

Authors:  Samuel R Birer; Chen-Ting Lee; Kingshuk Roy Choudhury; Kenneth H Young; Ivan Spasojevic; Ines Batinic-Haberle; James D Crapo; Mark W Dewhirst; Kathleen A Ashcraft
Journal:  Radiat Res       Date:  2017-05-18       Impact factor: 2.841

9.  Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma.

Authors:  Jürg Kutter; Mahmut Ozsahin; Philippe Monnier; Roger Stupp
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-03-05       Impact factor: 2.503

10.  Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients.

Authors:  Matthew Susko; Chia-Ching Jackie Wang; Ann A Lazar; Stephanie Kim; Angela Laffan; Mary Feng; Andrew Ko; Alan P Venook; Chloe E Atreya; Katherine Van Loon; Mekhail Anwar
Journal:  Oncologist       Date:  2020-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.